[Research progress of stearoyl-CoA desaturase-1 on obesity and non-alcoholic fatty liver disease Abstract].

Stearoyl-CoA desaturase-1 (SCD-1) is the key rate-limiting enzyme to catalyze the conversion of saturated fatty acids to monounsaturated fatty acids. The monounsaturated fatty acids in the catalytic products are important substrates for the formation of triglycerides, cholesteryl esters and phospholipids. Therefore, SCD-1 plays an important regulatory role in the metabolic process of fat. Currently, obesity and non-alcoholic fatty liver disease are widely prevalent worldwide. SCD-1 has gradually become a potential drug target for the treatment of such diseases due to its important regulatory role in fat metabolism. We summarize the recent research progress of SCD-1 in obesity and non-alcoholic fatty liver disease and the developmental status of SCD-1 inhibitors in order to provide new ideas and references related to disease and target drugs.硬脂酰辅酶A去饱和酶1（SCD-1）是催化饱和脂肪酸向单不饱和脂肪酸转化的关键限速酶，其催化产物单不饱和脂肪酸是甘油三酯、胆固醇酯、磷脂等形成的重要底物，因此SCD-1在脂肪代谢过程中发挥重要的调节作用。目前，肥胖及非酒精性脂肪性肝病在全球范围内广泛流行，基于SCD-1在脂肪代谢过程中发挥的重要调控作用，SCD-1逐渐成为此类疾病治疗的一个潜在药用靶点。现以SCD-1在脂肪代谢过程中发挥的生物学功能为背景，总结近年来SCD-1在肥胖和非酒精性脂肪性肝病中的研究概况及SCD-1抑制剂的研发现状，以期为相关疾病研究的开展和靶点药物的研发提供新的思路和参考。.